A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A

Journal of Immunology

Volumn 161, Issue 8, 1998, Pages 4115-4121

  Yamamoto, Masafumi ^a,b   Briles, David E ^a   Yamamoto, Shingo ^a   Ohmura, Mari ^a   Kiyono, Hiroshi ^a,b   McGhee, Jerry R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CD4 ANTIGEN; CHOLERA TOXIN; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 4; PNEUMOCOCCAL SURFACE PROTEIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; HELPER CELL; IMMUNIZATION; INFECTION PREVENTION; INTRANASAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; CHOLERA TOXIN; IMMUNITY, MUCOSAL; MICE; MICE, INBRED C57BL; MUTATION; PNEUMOCOCCAL INFECTIONS;

EID: 0032532645     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. MacLeod, C. M., R. G. Hodge, M. Heidelberger, and W. G. Bernhard. 1945. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 82:445.
2. Anderson, P., D. H. Smith, D. L. Ingram, J. Wilkins, P. F. Wehrle, and V. M. Howie. 1977. Antibody of polyribophate of Haemophilus influenzae type b in infants and children: effect of immunization with polyribophosphate. J. Infect. Dis. 136:S57.
3. Cowan, M. J., A. J. Ammann, D. W. Wara, V. M. Howie, L. Schultz, N. Doyle, and M. Kaplan. 1978. Pneumococcal polysaccharide immunization in infants and children. Pediatrics 62:721.
4. Kathy, H., and J. Eskola. 1996. New vaccines for the prevention of pneumococcal infections. Emerg. Infect. Dis. 2:289.
5. McDaniel, L. S., J. Yother, M. Vijayakumar, L. McGarry, W. R. Guild, and D. E. Briles. 1987. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J. Exp. Med. 165:381.
6. Berry, A. M., J. Yother, D. E. Briles, D. Hansman, and J. C. Paton. 1989. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Inject. Immun. 57:2037.
7. Berry, A. M., R. A. Lock, D. Hansman, and J. C. Paton. 1989. Contribution of autolysin to virulence of Streptococcus pneumoniae. Infect. Immun. 67:2324.
8. McDaniel, L. S., G. Scott, K. Widenhofer, J. M. Carroll, and D. E. Briles. 1986. Analysis of a surface protein of Streptococcus pneumoniae recognized by protective monoclonal antibodies. Microb. Pathog. 1:519.
9. Crain, M. J., W. D. Waltman, Jr., J. S. Turner, J. Yother, D. F. Talkington, L. S. McDaniel, B. M. Gray, and D. E. Briles. 1990. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect. Immun. 58:3293.
10. Briles, D. E., J. D. King, M. A. Gray, L. S. McDaniel, E. Swiatlo, and K. A. Benton. 1996. PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine 14:858.
11. McDaniel, L. S., G. Scott, J. F. Kearney, and D. E. Briles, 1984. Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J. Exp. Med. 160:386.
12. Talkington, D. F., D. L. Crimmins, D. C. Voellinger, J. Yother, and D. E. Briles. 1991. A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence. Infect. Immun. 59:1285.
13. Langermann, S., S. R. Palaszynski, J. E. Burlein, S. Koenig, M. S. Hanson, D. E. Briles, and C. K. Stover. 1994. Protective humoral response against pneumococcal infection in mice. J. Exp. Med. 180:2277.
14. Wu, H.-Y., M. Nahm, Y. Guo, M. W. Russell, and D. E. Briles. 1997. Intranasal immunization with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 175:839.
15. Yamamoto, M., L. S. McDaniel, K. Kawabata, D. E. Briles, R. J. Jackson, J. R. McGhee, and H. Kiyono. 1997. Oral immunization with PspA elicits protective humoral immunity. Infect. Immun. 65:640.
16. Yamamoto, S., Y. Takeda, M. Yamamoto, H. Kurazono, K. Imaoka, M. Yamamoto, K. Fujihashi, M. Noda, H. Kiyono, and J. R. McGhee. 1997. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185:1203.
17. Yamamoto, S., H. Kiyono, M. Yamamoto, K. Imaoka, M. Yamamoto, K. Fujihashi, F. W. van Ginkel, M. Noda, Y. Takeda, and J. R. McGhee. 1997. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA 94:5267.
18. Jackson, R. J., K. Fujihashi, A. J. Xu, H. Kiyono, C. O. Elson, and J. R. McGhee. 1993. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect. Immun. 61:4272.
19. van Ginkel, F. W., J. R. McGhee, C. Liu, J. W. Simecka, M. Yamamoto, R. A. Frizzell, E. J. Sorscher, H. Kiyono, and D. W. Pascual. 1997. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. J. Immunol. 159:685.
20. Mega J., J. R. McGhee, and H. Kiyono. 1992. Cytokine- and Ig-producing T cells in mucosal effector tissues: analysis of IL-5- and IFN-γ-producing T cells, T cell receptor expression, and IgA plasma cells fro mouse salivary gland-associated tissues. J. Immunol. 148:2030.
21. Hiroi, T., K. Fujihashi, J. R. McGhee, and H. Kiyono. 1995. Polarized Th2 cytokine expression by both musocal γδ and αβ T cells. Eur. J. Immunol. 25:2743.
22. Lu, W., D. S. Han, J. Yuan, and J. M. Andrieu. 1994. Multi-target PCR analysis by capillary electrophoresis and laser-induced fluorescence. Nature 368:269.
23. Yamamoto, M., K. Kawabata, K. Fujihashi, J. R. McGhee, T. E. VanDyke, T. V. Bamberg, T. Hiroi, and H. Kiyono. 1996. Absence of exogenous IL-4-induced apoptosis of gingival macrophage may contribute to chronic inflammation in periodontal diseases. Am. J. Pathol. 148:331.
24. + Th2 cells producing IL-6 and IL-10 are associated with mucosal IgA responses. Infect. Immun. 64:1516.
25. VanCott, J. L., H. F. Staats, D. W. Pascual, M. Roberts, S. N. Chatfield, M. Yamamoto, M. Coste, P. B. Carter, H. Kiyono, and J. R. McGhee. 1996. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. J. Immunol. 156:1504.
26. McDaniel, L. S., J. S. Sheffield, P. Delucchi, and D. E. Briles. 1991. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect. Immun. 59:222.
27. Tart, R. C., L. S. McDaniel, B. A. Ralph, and D. E. Briles. 1996. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J. Infect. Dis. 173:380.
28. Czerkinsky, C., M. W. Russell, N. Lycke, M. Lindblad, and J. Holmgren. 1989. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramusocal tissues. Infect. Immun. 57:1072.
29. Lee, A., and M. Chen. 1994. Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine. Infect. Immun. 62:3594.
30. McKenzie, S. J., and J. F. Halsey. 1984. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J. Immunol. 133:1818.
31. Tamura, S., Y. Samegai, H. Kurata, T. Nagamine, C. Aizawa, and T. Kurata. 1988. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6:409.
32. Wilson, A. D., C. J. Clarke, and C. R. Stokes. 1990. Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhold limpet haemocyanin. Scand. J. Immunol. 31:443.
33. Xu-Amano, J., H. Kiyono, R. J. Jackson, H. F. Staats, K. Fujihashi, P. D. Burrows, C. O. Elson, S. Pillai, and J. R. McGhee. 1993. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J. Exp. Med. 178:1309.
34. Marinaro, M., H. F. Staats, T. Hiroi, R. J. Jackson, M. Coste, P. N. Boyaka, N. Okahashi, M. Yamamoto, H. Kiyono, H. Bluethmann, K. Fujihashi, and J. R. McGhee. 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:4621.
35. Spangler, B. D. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622.
36. Gill, D. M., and C. A. King. 1975. The mechanisms of action of cholera toxin in pigeon erythrocytes. J. Biol. Chem. 250:6424.
37. Field, M., M. C. Rao, and E. B. Chang. 1989. Intestinal electrolyte transport and diarrheal disease. I. N. Engl. J. Med. 321:800.
38. Lycke, N., T. Tsuji, and J. Holmgren. 1992. The adjuvant effect of Vibio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:2277.
39. Di Tommaso, A., G. Saletti, M. Pizza, R. Rappuoli, G. Dougan, S. Abrignani, G. Douce, and M. T. DeMagistris. 1996. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64:974.
40. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile toxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617.
41. Douce, G., C. Turcotte, I. Cropley, M. Roberts, M. Pizza, M. Domenghini, R. Rappuoli, and G. Dougan. 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 92:1644.
42. Ågren, L. C., L. Ekman, B. Lowenadler, and N. Y. Lycke. 1997. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158:3936.
43. Cong, Y., C. T. Weaver, and C. O. Elson. 1997. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J. Immunol. 159:5301.